Spinogenix
Los Angeles, US · Founded 2016 · Delaware corporation
Spinogenix develops first-in-class small-molecule investigational therapeutics designed to restore brain synapses in neurodegenerative, neuropsychiatric, and neurodevelopmental conditions such as ALS, Alzheimer's disease, schizophrenia, and Fragile X Syndrome. It is a clinical-stage biopharmaceutical company advancing drug candidates through clinical trials.
BiotechDeep TechHealthtech
Founders & leadership
SS
Stella Sarraf, Ph.D.Executive Officer, Director
SS
Stella SarrafFounder & CEO
FH
Franz HeftiDirector
JS
Josh SwartzDirector
SY
Steve YoungDirector
JL
Jerre L. SteadDirector
MT
Mervyn Turner, Ph.D.Director
Competitors · 9
by search overlapDiabetes Prevention Program92 shared keywords
PatSnap69 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Bioworld47 shared keywordsBioWorld publishes news and data on the biopharmaceutical and drug development industry, covering topics such as clinical trials, licensing deals, oncology pipelines, and gene therapies. It serves biopharma and life sciences professionals through industry reporting and market intelligence.
Cowles_Investments_StemCentrx42 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
NCT0510118738 shared keywords
Biogen Idec31 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Clinicaltrialsarena30 shared keywordsClinical Trials Arena is an online news and information publication covering the clinical trials industry, including trends, regulatory developments, and industry events. It serves professionals working in pharmaceutical and clinical research.
Fda29 shared keywords
ResearchGate28 shared keywords
Companies competing with Spinogenix for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$10.6MraisedMar 2026 · 5 investors · Other Health CareRule 506(b)
▶$10.6MraisedMar 2026 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Steve YoungDirector
- Stella Sarraf, Ph.D.Executive Officer, Director
- Jerre L. SteadDirector
- Mervyn Turner, Ph.D.Director
- Offering amount
- $35M
- Amount sold
- $10.6M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.8MraisedJun 2024 · 3 investors · Other Health CareRule 506(b)
▶$2.8MraisedJun 2024 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mervyn TurnerDirector
- Dan AlbostaExecutive Officer
- Stella SarrafExecutive Officer, Director
- Peter Whitney VanderklishExecutive Officer
- Jerre SteadDirector
- Offering amount
- $25M
- Amount sold
- $2.8M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedAug 2023 · 3 investors · Other Health CareRule 506(b)
▶$5.2MraisedAug 2023 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Vincent SimmonExecutive Officer, Director
- Stella SarrafExecutive Officer, Director
- Mervyn TurnerDirector
- Peter Whitney VanderklishExecutive Officer
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedSep 2022 · 3 investors · Other Health CareRule 506(b)
▶$3.3MraisedSep 2022 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stella SarrafExecutive Officer, Director
- Peter Whitney VanderklishExecutive Officer
- Vincent SimmonExecutive Officer
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- First sale
- Sep 2022
- Incorporated
- Corporation, De
- Federal exemptions
- 06b
▶$1.6MraisedFeb 2021 · 22 investors · Other Health CareRule 506(b)
▶$1.6MraisedFeb 2021 · 22 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stella SarrafExecutive Officer, Director
- Franz HeftiDirector
- Vincent SimmonExecutive Officer
- Peter VanderklishExecutive Officer
- Offering amount
- $2.3M
- Amount sold
- $1.6M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedSep 2020 · 12 investors · Other Health CareRule 506(b)
▶$250KraisedSep 2020 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stella SarrafExecutive Officer, Director
- Vincent SimmonExecutive Officer
- Peter Whitney VanderklishExecutive Officer
- Franz HeftiDirector
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$903.3KraisedMay 2018 · 10 investors · Other Health CareRule 506(b)
▶$903.3KraisedMay 2018 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stella SarrafExecutive Officer, Director
- Franz HeftiDirector
- Josh SwartzDirector
- Offering amount
- $903.3K
- Amount sold
- $903.3K
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $314.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.